Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021
As Israeli Firm Publishes Full-Year Results
Feb 12 2021
•
By
Dean Rudge
Teva's generic operations in the US are worth around $4bn per year in revenues • Source: Shutterstock
More from Generics
More from Products